Immediate Impact
18 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
HER2-targeted therapies in cancer: a systematic review
2024 Standout
Works of David Tesarowski being referenced
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC)
2022
96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| David Tesarowski | 113 | 141 | 69 | 81 | 13 | 318 | |
| Saif Abu Mouch | 24 | 78 | 58 | 53 | 14 | 354 | |
| Michel Desnoyers | 80 | 145 | 39 | 108 | 15 | 339 | |
| Mary Beth Matychak | 20 | 141 | 31 | 52 | 12 | 280 | |
| V. C. SPEIRS | 46 | 175 | 25 | 37 | 18 | 261 | |
| Jennifer Taintor | 70 | 191 | 29 | 11 | 30 | 354 | |
| M. Julia B. Felippe | 16 | 39 | 57 | 15 | 14 | 358 | |
| Judith E. Saik | 99 | 56 | 17 | 5 | 20 | 294 | |
| Bridget C. Garner | 27 | 24 | 12 | 16 | 27 | 321 | |
| J. R. Bolton | 48 | 150 | 41 | 18 | 21 | 330 | |
| Lin Klein | 28 | 112 | 25 | 16 | 21 | 285 |
All Works
Loading papers...